Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The company commercializes Voquezna (vonoprazan), a potassium-competitive acid blocker (P-CAB) for erosive GERD and Helicobacter pylori infection. Principal revenue streams derive from commercial product sales of Voquezna prescription tablets to specialty pharmaceutical distributors, retail pharmacy chains, and health systems. Core end markets serve gastroenterology medical practices, primary care clinics, retail pharmacies, and prescription patients in the United States. Phathom Pharmaceuticals holds an innovative pioneer position in the US gastrointestinal pharmaceutical market as a developer of P-CAB acid suppression therapies. The corporation is headquartered in Florham Park, New Jersey, and its common stock trades on the Nasdaq Global Select Market.
3 of the funds FundTelligence covers report a position in Phathom Pharmaceuticals.
- Legal name
- Phathom Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Phathom Pharmaceuticals
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.33 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)